Use of broadly neutralizing antibodies for HIV-1 prevention

Amarendra Pegu, Ann Hessell, John R. Mascola, Nancy Haigwood

    Research output: Contribution to journalReview article

    53 Citations (Scopus)

    Abstract

    Antibodies have a long history in antiviral therapy, but until recently, they have not been actively pursued for HIV-1 due to modest potency and breadth of early human monoclonal antibodies (MAbs) and perceived insurmountable technical, financial, and logistical hurdles. Recent advances in the identification and characterization of MAbs with the ability to potently neutralize diverse HIV-1 isolates have reinvigorated discussion and testing of these products in humans, since new broadly neutralizing MAbs (bnMAbs) are more likely to be effective against worldwide strains of HIV-1. In animal models, there is abundant evidence that bnMAbs can block infection in a dose-dependent manner, and the more potent bnMAbs will allow clinical testing at infusion doses that are practically achievable. Moreover, recent advances in antibody engineering are providing further improvements in MAb potency, breadth, and half-life. This review summarizes the current state of the field of bnMAb protection in animal models as well as a review of variables that are critical for antiviral activity. Several bnMAbs are currently in clinical testing, and we offer perspectives on their use as pre-exposure prophylaxis (PrEP), potential benefits beyond sterilizing immunity, and a discussion of future approaches to engineer novel molecules.

    Original languageEnglish (US)
    Pages (from-to)296-312
    Number of pages17
    JournalImmunological Reviews
    Volume275
    Issue number1
    DOIs
    StatePublished - Jan 1 2017

    Fingerprint

    Neutralizing Antibodies
    HIV-1
    Monoclonal Antibodies
    Antiviral Agents
    Animal Models
    Antibodies
    Half-Life
    Immunity
    History
    Infection
    Therapeutics

    Keywords

    • Fc-effector functions
    • HIV-1 antibodies
    • Neutralizing antibodies
    • pre-exposure prophylaxis
    • SHIV protection

    ASJC Scopus subject areas

    • Immunology and Allergy
    • Immunology

    Cite this

    Use of broadly neutralizing antibodies for HIV-1 prevention. / Pegu, Amarendra; Hessell, Ann; Mascola, John R.; Haigwood, Nancy.

    In: Immunological Reviews, Vol. 275, No. 1, 01.01.2017, p. 296-312.

    Research output: Contribution to journalReview article

    Pegu, Amarendra ; Hessell, Ann ; Mascola, John R. ; Haigwood, Nancy. / Use of broadly neutralizing antibodies for HIV-1 prevention. In: Immunological Reviews. 2017 ; Vol. 275, No. 1. pp. 296-312.
    @article{d83b3e2c79174e0d9bbdd84a99c7ba7f,
    title = "Use of broadly neutralizing antibodies for HIV-1 prevention",
    abstract = "Antibodies have a long history in antiviral therapy, but until recently, they have not been actively pursued for HIV-1 due to modest potency and breadth of early human monoclonal antibodies (MAbs) and perceived insurmountable technical, financial, and logistical hurdles. Recent advances in the identification and characterization of MAbs with the ability to potently neutralize diverse HIV-1 isolates have reinvigorated discussion and testing of these products in humans, since new broadly neutralizing MAbs (bnMAbs) are more likely to be effective against worldwide strains of HIV-1. In animal models, there is abundant evidence that bnMAbs can block infection in a dose-dependent manner, and the more potent bnMAbs will allow clinical testing at infusion doses that are practically achievable. Moreover, recent advances in antibody engineering are providing further improvements in MAb potency, breadth, and half-life. This review summarizes the current state of the field of bnMAb protection in animal models as well as a review of variables that are critical for antiviral activity. Several bnMAbs are currently in clinical testing, and we offer perspectives on their use as pre-exposure prophylaxis (PrEP), potential benefits beyond sterilizing immunity, and a discussion of future approaches to engineer novel molecules.",
    keywords = "Fc-effector functions, HIV-1 antibodies, Neutralizing antibodies, pre-exposure prophylaxis, SHIV protection",
    author = "Amarendra Pegu and Ann Hessell and Mascola, {John R.} and Nancy Haigwood",
    year = "2017",
    month = "1",
    day = "1",
    doi = "10.1111/imr.12511",
    language = "English (US)",
    volume = "275",
    pages = "296--312",
    journal = "Immunological Reviews",
    issn = "0105-2896",
    publisher = "Wiley-Blackwell",
    number = "1",

    }

    TY - JOUR

    T1 - Use of broadly neutralizing antibodies for HIV-1 prevention

    AU - Pegu, Amarendra

    AU - Hessell, Ann

    AU - Mascola, John R.

    AU - Haigwood, Nancy

    PY - 2017/1/1

    Y1 - 2017/1/1

    N2 - Antibodies have a long history in antiviral therapy, but until recently, they have not been actively pursued for HIV-1 due to modest potency and breadth of early human monoclonal antibodies (MAbs) and perceived insurmountable technical, financial, and logistical hurdles. Recent advances in the identification and characterization of MAbs with the ability to potently neutralize diverse HIV-1 isolates have reinvigorated discussion and testing of these products in humans, since new broadly neutralizing MAbs (bnMAbs) are more likely to be effective against worldwide strains of HIV-1. In animal models, there is abundant evidence that bnMAbs can block infection in a dose-dependent manner, and the more potent bnMAbs will allow clinical testing at infusion doses that are practically achievable. Moreover, recent advances in antibody engineering are providing further improvements in MAb potency, breadth, and half-life. This review summarizes the current state of the field of bnMAb protection in animal models as well as a review of variables that are critical for antiviral activity. Several bnMAbs are currently in clinical testing, and we offer perspectives on their use as pre-exposure prophylaxis (PrEP), potential benefits beyond sterilizing immunity, and a discussion of future approaches to engineer novel molecules.

    AB - Antibodies have a long history in antiviral therapy, but until recently, they have not been actively pursued for HIV-1 due to modest potency and breadth of early human monoclonal antibodies (MAbs) and perceived insurmountable technical, financial, and logistical hurdles. Recent advances in the identification and characterization of MAbs with the ability to potently neutralize diverse HIV-1 isolates have reinvigorated discussion and testing of these products in humans, since new broadly neutralizing MAbs (bnMAbs) are more likely to be effective against worldwide strains of HIV-1. In animal models, there is abundant evidence that bnMAbs can block infection in a dose-dependent manner, and the more potent bnMAbs will allow clinical testing at infusion doses that are practically achievable. Moreover, recent advances in antibody engineering are providing further improvements in MAb potency, breadth, and half-life. This review summarizes the current state of the field of bnMAb protection in animal models as well as a review of variables that are critical for antiviral activity. Several bnMAbs are currently in clinical testing, and we offer perspectives on their use as pre-exposure prophylaxis (PrEP), potential benefits beyond sterilizing immunity, and a discussion of future approaches to engineer novel molecules.

    KW - Fc-effector functions

    KW - HIV-1 antibodies

    KW - Neutralizing antibodies

    KW - pre-exposure prophylaxis

    KW - SHIV protection

    UR - http://www.scopus.com/inward/record.url?scp=85010902371&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85010902371&partnerID=8YFLogxK

    U2 - 10.1111/imr.12511

    DO - 10.1111/imr.12511

    M3 - Review article

    C2 - 28133803

    AN - SCOPUS:85010902371

    VL - 275

    SP - 296

    EP - 312

    JO - Immunological Reviews

    JF - Immunological Reviews

    SN - 0105-2896

    IS - 1

    ER -